TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age \> 18 years.~2. Patients diagnosed with localized scleroderma diseases during inactive stage with fibrotic and atrophic cutaneous lesions confirmed histologically.~3. Understanding the nature of the study and Signature of the written informed consent.~4. Negative pregnancy test at study entry for females of child bearing potential.~5. If the patient is a female of childbearing potential (less than 24 months since the last menstrual bleeding), she is using an acceptable and effective method of contraception during the study period.~Exclusion Criteria:~1. Patients under treatment with steroid therapy and/or systemic immunosuppressive therapy within 1 month prior to screening.~2. Patients with ongoing infectious processes at the level of target lesions.~3. Women who are pregnant or breast feeding.~4. Know allergy or hypersensitivity to the active principle of the investigational drug or to one of its excipients.~5. Patients with a condition or concurrent severe and/or uncontrolled medical disease which could compromise his/her participation, compliance with and/or completion of study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polydeoxyribonucleotides (Type: EXPERIMENTAL): PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Flow Anaesthesia, is There a Difference Between 2 Modern Anaesthetic Machines Using Different Gas Reservoir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~ASA 1-2 patient 18 - 65 years scheduled for elective surgery~Exclusion Criteria:~ASA \> 2 heart failure COPD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Flow-I (Type: EXPERIMENTAL): Wash in of desflurane (SupraneR) in an anaesthesia machine without below, a new technique that do not have abag/reservoir that is compressed but pushes the gas into the patient. This technique uses far less of fresh gas volume. Thus lower anaesthetic gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used.
- Asys (Type: ACTIVE_COMPARATOR): Wash in of desflurane (Suprane) in conventional anaesthesia machine Asys, with the anaesthesia machine Asys that has a bag/reservoir that is compressed for insufflation of gas into the patient, thus it is expected that more gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a New Imagingtechnologie for Thrombosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AAA (diameter \>3.5cm in duplex sonography) or acute DVT.~* Male and female patients 18 years and older,~* Signed Informed Consent after being informed~Exclusion Criteria:~* contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,~* women who are pregnant or breast feeding,~* women with the intention to become pregnant during the course of the study,~* other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease),~* renal clearance \< 30 mL/min~* known or suspected non-compliance, drug or alcohol abuse,~* inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject,~* participation in another study with an investigational drug during the present study and 7 days thereafter.~* enrolment of the investigator, his family members, employees and other dependent persons~* last systemic treatment with GP IIb/IIIa antagonists should not have been applied within 48 h before performing study exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnosis with GP1 (Type: EXPERIMENTAL): Injection and scanning of \[18F\]-GP1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Subjects who meet all of the following criteria may be included in the study:~1. Must have a diagnosis of primary myelodysplastic syndromes (MDS) of Intermediate-1 transfusion dependent, Intermediate-2, or High-risk \[defined by International Prognostic Scoring System (IPSS) score of ≥0.5\] and recognized French-American-British (FAB) classifications~2. Male or female, 18 years of age or older with signed informed consent~3. Adequate renal function~4. Demonstrated normal liver function~5. Female subjects of childbearing age must have negative pregnancy test within 1 week of study entry and agree to use adequate contraception for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received.~6. Male subjects must agree to use adequate contraception for the duration of the trial and for a minimum of six months after last dose of decitabine or azacitidine received.~Exclusion Criteria~Subjects who meet any of the following criteria will be excluded from participation in the study:~1. Current use of radiotherapy for extramedullary disease for 2 weeks prior to entering study (permitted if \> 2 weeks from study entry and if recovered from toxic effects of therapy)~2. Systemic fungal, bacterial, or viral infection which is not controlled (i.e., ongoing signs or symptoms of infection and without improvement despite appropriate treatment)~3. Pregnancy or current lactation~4. Significant concurrent disease, illness, or psychiatric disorder~5. Treatment with an investigational agent 30 days prior to the first dose of decitabine or azacitidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over 18 years~* CML Philadelphia chromosome in chronic phase treated with nilotinib or ponatinib for, in first or second line~* Written informed consent must be obtained prior to protocol-specific procedures~* Affiliation to a social security category~Exclusion Criteria:~* Revascularization already decided and scheduled~* Life threatening disease~* Recent history of myocardial infarction or stroke~* Unstable angina~* Hypotension (Blood pressure \< 90/50mmHg)~* Pregnancy and lactation~* Women of childbearing potential not using appropriate contraceptive measures~* Contraindication for statin~* Contraindication for aspirin~* Contraindication for ACEi or AT2 antagonists treatment~* Known hypersensitivity to rosuvastatin or fluvastatin, other ingredients in the product~* Known hypersensitivity to aspirin, other ingredients in the product, other salicylates or non-steroidal anti-inflammatory drugs~* Known hypersensitivity to ACEi or AT2 antagonists treatment, other ingredients in the product~* Hereditary or idiopathic angioedema ; or history of angioedema~* Hyperaldosteronism~* Active liver disease, or unexplained, persistent elevations in serum transaminases~* Severe renal impairment (creatinine clearance \<30 ml/min)~* Myopathy~* Concomitant cyclosporine treatment~* History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy~* Severe heart failure~* Concurrent severe diseases which exclude the administration of therapy~* Patients under reinforced protection, deprived of liberty by judicial or administrative decision, hospitalized without consent or admitted to a health or social establishment for purposes other than research~* Absence of affiliation to a social security agency~* Inability to understand the instructions or objectives of the study~* Absence of signed informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active prevention (Type: EXPERIMENTAL): optimal medical treatment
- usual clinical practice (Type: SHAM_COMPARATOR): usual clinical practice in each center

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality in SOD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic biliary type abdominal pain (RUQ pain, pain radiates to the right flank, scapula, or shoulder, or pain that stimulates gallbladder symptoms)~* Pancreatic pain (epigastric or left upper quadrant pain, pain that is exacerbated by some food, or pain that radiates to the back) for at least 3 months prior to the study~* absence of abnormal liver and pancreas chemistry or abnormal abdominal imaging~* average pain score of greater than or equal to 3 out of 10 on the numeric rating scale (NRS) for at least the average of 3 episodes each week~* Subjects on antidepressants for pain control should take the medication for a minimum of one month prior to the baseline assessment.~* Patients with SOD with depressive and/or anxiety disorders who receive psychopharmacologic treatment must be on stable medication dose for at least 6 weeks.~* Patients with access to a cell phone, able to speak, read, and write English will be enrolled.~Exclusion Criteria:~* Patients with evidence for acute or chronic pancreatitis, biliary stones, or bile duct strictures.~* Patients who have had prior sphincterotomy must have had the procedure at 3 months prior to the start of the study.~* Patients with a history of motion sickness and vertigo and anyone experiencing active nausea or vomiting (including pregnant women) will be excluded.~* Patients with a history of seizures or epilepsy will also be excluded to limit the theoretical risk of inducing seizures with VR.~* Presence of significant psychiatric disorders or any conditions that, in the investigator's opinion make the subject unsuitable for study participation will be reason for exclusion.~* Non-English speaking subjects or subjects unable to consent to study due to cognitive difficulty will not be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Virtual Reality (Type: EXPERIMENTAL): Every participant is provided with a VR headset

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Respiratory Physiotherapy Allow for Earlier Withdrawal of Mechanical Ventilation in Respiratory Resuscitation Service?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult~* Major Patient over 18 years of age~* Patient affiliated to social security~Exclusion Criteria:~* Sedate~* With restrictive or tracheotomized syndrome~* With rib fractures~* Not able to benefit from physiotherapy within 3 hours after the start of the weaning protocol~* Refusal of patient or family~* Physiotherapy contraindications~* Patient under tutorship or curatorship~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient receiving respiratory physiotherapy (Type: OTHER): None
- Patient not receiving respiratory physiotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 Diabetes Mellitus~* Postmenopausal female~* Age \>55 years~* Hemoglobin A1c between 7-10% within 6 months of the first visit.~Exclusion Criteria:~* Patients with type 1 Diabetes mellitus~* Patients with a history of GLP-1 receptor agonist/DPP4 inhibitor use~* eGFR \<30 ml/min in the last 3 months~* Patients with a history of pancreatitis~* Personal or family history of medullary thyroid cancer~* Patients with a history of treatment with anti-osteoporosis agents~* Documented secondary osteoporosis~* Documented presence of prosthesis or devices in the spine~* Unwilling or unable to consent

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLP-1 cohort (Type: EXPERIMENTAL): Participants on GLP-1 receptor agonists
- Non GLP-1 cohort (Type: NO_INTERVENTION): Participants not on GLP-1 receptor agonists

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine-Associated Psychosis.~2. Must sign a Information consent form.~3. Required to provide detailed address and phone number~Exclusion Criteria:~1. Serious organic disease.~2. Suicide ideation or hurt others.~3. Taking antipsychotic within two weeks before.~4. drug allergy to Risperidone or Aripiprazole.~5. pregnancy and breastfeeding women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatments of the Necrosed Immature Teeth (REV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients presenting one or monoradicular immature definitive several teeth ( open apex) with a pulpar necrosis,~* 6-year-old patients in 17 years the parents(relatives) of which agree to give a lit(enlightened) written consent or patients of more than 18 years old.~Exclusion Criteria:~* general order: any pathology or treatment(processing) dissuading a treatment(processing) endodontic (patients at risk of infectious endocarditis) or pulling(entailing) an immunosuppression (diabetes, HIV, immunosuppresseurs treatments(processings) post-transplant, long-term corticoids, chemotherapies), allergy known about the used, antecedent products of cervico-facial radiotherapy, presenting subject of the communications problems, the pregnancy and the feeding.~* local order: generalized periodontal disease or superior located(localized) periodontal pocket in 3mm, crack or fracture(split) radiculaire, radiculaire reduction of the necrosed immature tooth

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional technique (Type: PLACEBO_COMPARATOR): Apical MTA barrier
- Revascularisation pulpaire (Type: EXPERIMENTAL): hydroxide of calcium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Heart Failure and Peritoneal Ultrafiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with congestive heart failure (CHF) who remain fluid overloaded despite standard treatment.~Exclusion Criteria:~* Patients who have reversible CHF or have diseases or conditions that would contraindicate the use of peritoneal dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): peritoneal dialysis
- Standard of Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of Fanconi Anemia or other suspected DNA breakage/chromosomal instability syndromes, such as dyskeratosis congenita or Nijmegen breakage syndrome of all ages are eligible.~Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow sensitivity to mitomycin C or DEB or clinical evidence of other DNA breakage/chromosomal instability syndrome as determined by genetic testing or clinical diagnosis by a geneticist~Severe aplasia anemia as evidenced by a hypocellular bone marrow and at least 1 of the 3 criteria below: ANC \< 500/mm3 Hemoglobin \< 10 gm/dl with reticulocyte count \< 1% Platelet count \< 50,000/mm3~Availability of an HLA matched or mismatched (up to one haplotype) family member who has been documented not to have Fanconi anemia or of an unrelated HLA matched stem cell donor. Fully matched is defined at 6/6 match by high resolution DR based DNA typing.~Life expectancy greater than 6 weeks limited by diseases other than FA~Creatinine 2X normal for age or less~Karnofsky score 70% or more~Exclusion Criteria:~Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction less than 25%).~Patients with known allergy to rat serum products.~Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation.~Patients with severe personality disorder or mental illness.~Patients with documented HIV positivity.~Pregnant~NOTE: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA Reviewer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm Study: Stem Cell Transplant (Type: EXPERIMENTAL): CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues